Biomarker modelling of early molecular changes in Alzheimer's disease

Molecular Diagnosis and Therapy

Volumn 18, Issue 2, 2014, Pages 213-227

  Paterson, Ross W ^a   Toombs, Jamie ^a   Slattery, Catherine F ^a   Schott, Jonathan M ^a   Zetterberg, Henrik ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AUTOANTIBODY; BETA SECRETASE; BIOLOGICAL MARKER; COMPLEMENT; ISOPROSTANE DERIVATIVE; SORLA PROTEIN; UNCLASSIFIED DRUG; VISININ LIKE PROTEIN 1;

AGING; ALZHEIMER DISEASE; BRAIN; CEREBROSPINAL FLUID; EARLY DIAGNOSIS; HUMAN; MODEL; MOLECULAR BIOLOGY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COHORT STUDIES; EARLY DIAGNOSIS; HUMANS;

EID: 84897427910     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0069-9     Document Type: Review

References (172)

1. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease - the challenges ahead. Nat Rev Neurol. 2013;9(1):54-8. doi:10.1038/nrneurol.2012. 241.
2. Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3-12. (Pubitemid 26143161)
3. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord. 2000;14(Suppl 1):S47-53. (Pubitemid 30406772)
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353- 6. doi:10.1126/science.1072994. (Pubitemid 34790756)
5. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461(7266):916-22. doi:10.1038/nature08538.
6. Zetterberg H, Blennow K. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come? J Alzheimers Dis. 2013;33(Suppl 1):S361-9. doi:10.3233/JAD-2012-129035.
7. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33. doi:10.1126/scitranslmed.3002609.
8. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-34. doi:10.1016/S1474-4422(06)70355-6. (Pubitemid 43238346)
9. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-13. doi:10.1002/ana.21610.
10. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619-27. doi:10.1016/S1474-4422(09)70139-5.
11. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-93. doi:10.1001/jama.2009.1064.
12. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement. 2011;7(2):133-41. doi:10.1016/j.jalz.2010.08.230.
13. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336-45. doi:10.1373/clinchem.2004.039347. (Pubitemid 40175803)
14. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin Chem. 2012;58(4):787-9. doi:10.1373/clinchem.2011. 178368.
15. Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD et al. Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med. 2013:1-7. doi:10.1515/cclm-2013-0293.
16. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68(9):666-9. doi:10.1212/01.wnl.0000256043.50901.e3. (Pubitemid 46667813)
17. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem. 2005;51(1):189-95. doi:10.1373/clinchem.2004.039735. (Pubitemid 40024030)
18. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis. 2010;2010. doi:10.4061/2010/986310.
19. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7(4):386.e6-395.e6. doi:10.1016/j.jalz.2011.05.2243.
20. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9(3):251-61. doi:10.1016/j.jalz.2013.01.010.
21. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement. 2012. doi:10.1016/j.jalz.2012.11.003.
22. Bartlett JW, Frost C, Mattsson N, Skillback T, Blennow K, Zetterberg H, et al. Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. Biomark Med. 2012;6(4):391-400. doi:10.2217/bmm.12.49.
23. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology. 1999;52(8):1687-9. (Pubitemid 29220648)
24. Kaye JA, Swihart T, Howieson D, Dame A, Moore MM, Karnos T, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology. 1997;48(5):1297-304. (Pubitemid 27240552)
25. Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet. 1999;353(9170):2125. (Pubitemid 29278484)
26. Jack CR Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65(8):1227-31. (Pubitemid 41508215)
27. Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet. 2004;363(9406):392-4. doi:10.1016/S0140-6736(04)15441-X. (Pubitemid 38169550)
28. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-28. doi:10.1016/S1474-4422(09)70299-6.
29. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20(3):843-54. doi:10.3233/JAD-2010- 091504.
30. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med Technol. 2013;41(1):11-8. doi:10.2967/jnumed.110.076315.
31. Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Tamminen JN, Tillgren T, et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol. 2010;68(4):446-53. doi:10.1002/ana.22100.
32. Seppala TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 2012;78(20):1568-75. doi:10.1212/WNL.0b013e3182563bd0.
33. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging betaamyloid pathology. JAMA. 2011;305(3):275-83. doi:10.1001/jama.2010.2008.
34. Ryan NS, Rossor MN. Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomark Med. 2010;4(1):99-112.
35. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain. 1996;119(Pt 6):2001-7.
36. Schott JM, Fox NC, Frost C, Scahill RI, Janssen JC, Chan D, et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol. 2003;53(2):181-8. doi:10.1002/ana.10424. (Pubitemid 36163999)
37. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006;5(10):828-34. doi:10.1016/S1474-4422(06)70550-6. (Pubitemid 44715810)
38. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753.
39. Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez de Llano S, Edison P, et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain. 2011;134(Pt 1):293-300. doi:10.1093/brain/awq310.
40. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27(23):6174-84. doi:10.1523/JNEUROSCI.0730-07.2007. (Pubitemid 46890033)
41. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, et al. Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189):189ra77. doi:10.1126/ scitranslmed.3005615.
42. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010;330(6012):1774. doi:10.1126/science.1197623.
43. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a casecontrol study. Lancet Neurol. 2012;11(12):1048-56. doi:10.1016/S1474-4422(12)70228-4.
44. Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol. 2010;68(6):825-34. doi:10.1002/ana.22315.
45. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-83. doi:10.1016/j. neurobiolaging.2010.04.007.
46. Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK, et al. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PloS One. 2013;8(3):e58816. doi:10.1371/journal.pone.0058816.
47. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310-23. doi:10.1093/brain/awn320.
48. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-67. doi:10.1016/S1474-4422(13)70044-9.
49. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-16. doi:10.1016/S1474-4422(12)70291-0.
50. Knopman DS, Roberts RO. Healthy young hearts sharper older minds make. Ann Neurol. 2013;73(2):151-2. doi:10.1002/ana.23847.
51. Chetelat G. Alzheimer disease: Abeta-independent processes-rethinking preclinical AD. Nat Rev Neurol. 2013;9(3):123-4. doi:10.1038/nrneurol.2013.21.
52. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-46. doi:10.1016/S1474- 4422(07)70178-3. (Pubitemid 47058377)
53. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9. doi:10.1016/j.jalz.2011.03.005.
54. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-9. doi:10.1016/j.jalz.2011.03.008.
55. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-92. doi:10.1016/j.jalz.2011.03.003.
56. Lam B, Masellis M, Freedman M, Stuss DT, Black SE. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimers Res Ther. 2013;5(1):1. doi:10.1186/alzrt155.
57. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16(9):903-7. doi:10.1038/mp.2011.52.
58. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology. 2004;62(11):2116-8. (Pubitemid 38738236)
59. Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, et al. CSF biomarkers for Alzheimer's pathology and the effect size of APOE varepsilon4. Mol Psychiatry. 2013. doi:10.1038/mp.2013.18.
60. Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D'Angelo G, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J Neurosci. 2010;30(50):17035-40. doi:10.1523/JNEUROSCI.3987-10.2010.
61. Scarmeas N, Habeck CG, Stern Y, Anderson KE. APOE genotype and cerebral blood flow in healthy young individuals. JAMA. 2003;290(12):1581-2. doi:10.1001/jama.290.12.1581. (Pubitemid 37430382)
62. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-41. doi:10.1038/ng.801.
63. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117-27. doi:10.1056/NEJMoa1211851.
64. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med. 2012;6(4):455-76. doi:10.2217/bmm.12.42.
65. Lo JT. Functional model of biological neural networks. Cogn Neurodyn. 2010;4(4):295-313. doi:10.1007/s11571-010-9110-4.
66. Zhang Y, Schuff N, Du AT, Rosen HJ, Kramer JH, Gorno-Tempini ML, et al. White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. Brain. 2009;132(Pt 9):2579-92. doi:10.1093/brain/awp071.
67. Gusnard DA, Raichle ME, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci. 2001;2(10):685-94. (Pubitemid 33674814)
68. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709-17. doi:10.1523/JNEUROSCI.2177-05.2005. (Pubitemid 41208641)
69. Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29(6):1860-73.
70. Lehmann M, Koedam EL, Barnes J, Bartlett JW, Barkhof F, Wattjes MP, et al. Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiol Aging. 2013;34(1):73-82. doi:10.1016/j. neurobiolaging.2012.03.010.
71. Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2007;104(47):18760-5. doi:10.1073/pnas.0708803104. (Pubitemid 350210770)
72. Petrella JR, Sheldon FC, Prince SE, Calhoun VD, Doraiswamy PM. Default mode network connectivity in stable vs progressive mild cognitive impairment. Neurology. 2011;76(6):511-7.
73. Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain. 2010;133(Pt 5):1352-67. doi:10.1093/brain/awq075.
74. Warren JD, Rohrer JD, Schott JM, Fox NC, Hardy J, Rossor MN. Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci. 2013. doi:10.1016/j.tins.2013.06.007.
75. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094-108. doi:10.1016/j.neuron. 2013.07.037.
76. Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, et al. A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis. 2012;31(3):601-12. doi:10.3233/JAD-2012-120712.
77. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457-68. doi:10.3233/JAD-122059.
78. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54(8):1420-7. doi:10.2967/jnumed.112.117341.
79. Nalivaeva NN, Turner AJ. The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett. 2013;587(13):2046-54. doi:10.1016/j.febslet.2013.05.010.
80. Abramsson A, Kettunen P, Banote RK, Lott E, Li M, Arner A, et al. The zebrafish amyloid precursor protein-b is required for motor neuron guidance and synapse formation. Dev Biol. 2013;381(2):377-88. doi:10.1016/j.ydbio.2013.06. 026.
81. Octave JN, Pierrot N, Ferao Santos S, Nalivaeva NN, Turner AJ. From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein. J Neurochem. 2013;126(2):183-90. doi:10.1111/jnc. 12239.
82. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18(2):291-5. doi:10.1038/nm.2613.
83. Borroni B, Pilotto A, Bonvicini C, Archetti S, Alberici A, Lupi A, et al. Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. Neurol Sci. 2012;33(2):375-8. doi:10.1007/s10072-011-0714-1.
84. Zainaghi IA, Talib LL, Diniz BS, Gattaz WF, Forlenza OV. Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease. J Neural Transm. 2012;119(7):815-9. doi:10.1007/s00702-012-0807-x.
85. Srisawat C, Junnu S, Peerapittayamongkol C, Futrakul A, Soiampornkul R, Senanarong V, et al. The platelet amyloid precursor protein ratio as a diagnostic marker for Alzheimer's disease in Thai patients. J Clin Neurosci. 2013;20(5):644-8. doi:10.1016/j.jocn.2012.06.008.
86. Jelic V, Hagman G, Yamamoto NG, Teranishi Y, Nishimura T, Winblad B, et al. Abnormal platelet amyloid-beta protein precursor (AbetaPP) metabolism in Alzheimer's disease: identification and characterization of a new AbetaPP isoform as potential biomarker. J Alzheimers Dis. 2013;35(2):285-95. doi:10.3233/JAD-122122.
87. Grimmer T, Wutz C, Drzezga A, Forster S, Forstl H, Ortner M, et al. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res. 2013;10(1):82-5.
88. Mattsson N, Ruetschi U, Pijnenburg YA, Blankenstein MA, Podust VN, Li S, et al. Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Mol Med Rep. 2008;1(5):757-61. doi:10.3892/mmr- 00000025.
89. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron. 2007;54(5):721-37. doi:10.1016/j.neuron.2007.05.012. (Pubitemid 46843521)
90. Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G. Increased beta-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol. 2004;55(6):898-9. doi:10.1002/ana.20144. (Pubitemid 38702591)
91. Barao S, Zhou L, Adamczuk K, Vanhoutvin T, Leuven F, Demedts D, et al. BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. Curr Alzheimer Res. 2013;10(7):671-8.
92. Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, et al. BACE1 inhibition induces a specific cerebrospinal fluid beta-amyloid pattern that identifies drug effects in the central nervous system. PloS One. 2012;7(2):e31084. doi:10.1371/journal.pone.0031084.
93. Pera M, Alcolea D, Sanchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol. 2013;125(2):201-13. doi:10.1007/s00401-012-1062-9.
94. Bibl M, Esselmann H, Wiltfang J. Neurochemical biomarkers in Alzheimer's disease and related disorders. Ther Adv Neurol Disord. 2012;5(6):335-48. doi:10.1177/1756285612455367.
95. Sjögren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E, et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord. 2001;12(4):257-64. doi:10.1159/000051268. (Pubitemid 32429725)
96. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol. 2010;223(2):366-70. doi:10.1016/j.expneurol.2009.07.024.
97. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Neuromol Med. 2012;14(1):65-73. doi:10.1007/s12017-012- 8171-4.
98. Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, et al. Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease. Brain Res. 2013;1513:117-26. doi:10.1016/j.brainres.2013.03.019.
99. Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Forster S, et al. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature. J Alzheimers Dis. 2013;36(2):401-8. doi:10.3233/JAD-122329.
100. Perneczky R, Guo LH, Kagerbauer SM, Werle L, Kurz A, Martin J, et al. Soluble amyloid precursor protein beta as blood-based biomarker of Alzheimer's disease. Transl Psychiatry. 2013;3:e227. doi:10.1038/tp.2013.11.
101. Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, et al. Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. J Neurosci Res. 2012;90(12):2247-58. doi:10.1002/jnr.23122.
102. Walsh ST, Kossiakoff AA. Crystal structure and site 1 binding energetics of human placental lactogen. J Mol Biol. 2006;358(3):773-84. doi:10.1016/j.jmb.2006.02.038.
103. Young-Collier KJ, McArdle M, Bennett JP. The dying of the light: mitochondrial failure in Alzheimer's disease. J Alzheimers Dis. 2012;28(4):771-81. doi:10.3233/JAD-2011-111487.
104. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, et al. Globular amyloid beta-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem. 2005;95(3):834-47. doi:10.1111/j.1471-4159.2005.03407.x. (Pubitemid 41567174)
105. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol.2013;73(1):104-19. doi:10.1002/ana.23748.
106. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, et al. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol. 2005;58(1):147-50. doi:10.1002/ana.20524. (Pubitemid 40962471)
107. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA. 2005;102(7):2273-6. doi:10.1073/pnas.0409336102. (Pubitemid 40279365)
108. Santos AN, Torkler S, Nowak D, Schlittig C, Goerdes M, Lauber T, et al. Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. J Alzheimers Dis. 2007;11(1):117-25. (Pubitemid 46376713)
109. Gatson JW, Warren V, Abdelfattah K, Wolf S, Hynan LS, Moore C, et al. Detection of beta-amyloid oligomers as a predictor of neurological outcome after brain injury. J Neurosurg. 2013;118(6):1336-42. doi:10.3171/2013.2.JNS121771.
110. Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H, et al. Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci. 2008;28(4):788-97. doi:10.1523/JNEUROSCI.4771-07.2008. (Pubitemid 351159014)
111. Holtta M, Hansson O, Andreasson U, Hertze J, Minthon L, Nagga K, et al. Evaluating amyloid-beta oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PloS One. 2013;8(6):e66381. doi:10.1371/journal.pone. 0066381.
112. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol. 1995;37(3):294-9. doi:10.1002/ana.410370305.
113. Fei M, Jianghua W, Rujuan M, Wei Z, Qian W. The relationship of plasma Abeta levels to dementia in aging individuals with mild cognitive impairment. J Neurol Sci. 2011;305(1-2):92-6. doi:10.1016/j.jns.2011.03.005.
114. Seppala TT, Herukka SK, Hanninen T, Tervo S, Hallikainen M, Soininen H, et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry. 2010;81(10):1123-7. doi:10.1136/jnnp.2010.205757.
115. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64(3):354-62. doi:10.1001/archneur.64.3.354. (Pubitemid 46425689)
116. Figurski MJ, Waligorska T, Toledo J, Vanderstichele H, Korecka M, Lee VM, et al. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement. 2012;8(4):250-60. doi:10.1016/j.jalz.2012.01.001.
117. Schott JM, Revesz T. Inflammation in Alzheimer's disease: insights from immunotherapy. Brain. 2013;136(Pt 9):2654-6. doi:10.1093/brain/awt231.
118. Colasanti T, Barbati C, Rosano G, Malorni W, Ortona E. Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression. Autoimmun Rev. 2010;9(12):807-11. doi:10.1016/j.autrev.2010.07.008.
119. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromol Med. 2003;3(1):29-39. (Pubitemid 37070580)
120. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57(5):801-5. (Pubitemid 32845498)
121. Henkel AW, Dittrich PS, Groemer TW, Lemke EA, Klingauf J, Klafki HW, et al. Immune complexes of auto-antibodies against A beta 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. Mol Psychiatry. 2007;12(6):601-10. doi:10.1038/sj.mp.4001947. (Pubitemid 46816767)
122. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol. 2001;49(6):808-10.
123. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA. 2009;106(29):12145-50. doi:10.1073/pnas.0904866106.
124. Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization. Brain. 2013;136(Pt 9):2677-96. doi:10.1093/brain/ awt210.
125. Gustafsen C, Glerup S, Pallesen LT, Olsen D, Andersen OM, Nykjaer A, et al. Sortilin and SorLA display distinct roles in processing and trafficking of amyloid precursor protein. J Neurosci. 2013;33(1):64-71. doi:10.1523/JNEUROSCI. 2371-12.2013.
126. Willnow TE, Andersen OM. Sorting receptor SORLA-a trafficking path to avoid Alzheimer disease. J Cell Sci. 2013;126(Pt 13):2751-60. doi:10.1242/jcs.125393.
127. Schmidt V, Baum K, Lao A, Rateitschak K, Schmitz Y, Teichmann A, et al. Quantitative modelling of amyloidogenic processing and its influence by SORLA in Alzheimer's disease. EMBO J. 2012;31(1):187-200. doi:10.1038/emboj.2011.352.
128. Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61(8):1200-5. doi:10.1001/archneur.61.8.1200. (Pubitemid 39062672)
129. Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65(9):866-72. doi:10.1097/01.jnen.0000228205.19915.20. (Pubitemid 44371232)
130. Alexopoulos P, Guo LH, Tsolakidou A, Kratzer M, Grimmer T, Westerteicher C, et al. Interrelations between CSF soluble AbetaPPbeta, amyloid-beta 1-42, SORL1, and tau levels in Alzheimer's disease. J Alzheimers Dis. 2012;28(3):543-52. doi:10.3233/JAD-2011-110983.
131. Tsolakidou A, Alexopoulos P, Guo LH, Grimmer T, Westerteicher C, Kratzer M, et al. Beta-site amyloid precursor proteincleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau. Alzheimers Dement. 2013;9(4):386-91. doi:10.1016/j.jalz.2012.01.015.
132. Dinkel PD, Siddiqua A, Huynh H, Shah M, Margittai M. Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. Biochemistry. 2011;50(20):4330-6. doi:10.1021/bi2004685.
133. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30(5):682-90. doi:10.1016/j.neurobiolaging. 2007.08.010.
134. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 2000;33(1):95-130.
135. Billingsley ML, Kincaid RL. Regulated phosphorylation and
136. Uchihara T, Hara M, Nakamura A, Hirokawa K. Tangle evolution linked to differential 3- and 4-repeat tau isoform deposition: a double immunofluorolabeling study using two monoclonal antibodies. Histochem Cell Biol. 2012;137(2):261-7. doi:10.1007/s00418-011-0891-2.
137. Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M. "Prion-like" templated misfolding in tauopathies. Brain Pathol. 2013;23(3):342-9. doi:10.1111/bpa.12044.
138. Gile GH, Faktorova D, Castlejohn CA, Burger G, Lang BF, Farmer MA, et al. Distribution and phylogeny of EFL and EF-1alpha in Euglenozoa suggest ancestral co-occurrence followed by differential loss. PloS One. 2009;4(4):e5162. doi:10.1371/journal.pone.0005162.
139. Luk C, Compta Y, Magdalinou N, Marti MJ, Hondhamuni G, Zetterberg H, et al. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem. 2012;123(3):396-405. doi:10.1111/j.1471-4159.2012. 07911.x.
140. Yang FM, Grigorenko A, Tommet D, Farias ST, Mungas D, Bennett DA, et al. AD pathology and cerebral infarctions are associated with memory and executive functioning one and five years before death. J Clin Exp Neuropsychol. 2012. doi:10.1080/13803395.2012.740001.
141. Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008;54(10):1617-23. doi:10.1373/ clinchem.2008.104497.
142. Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70(2):274-85. doi:10.1002/ana.22448.
143. Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, et al. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. J Neurochem. 2013. doi:10.1111/jnc.12331.
144. Braunewell KH. The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer's disease-old wine in new bottles. Front Mol Neurosci. 2012;5:20. doi:10.3389/fnmol.2012.00020.
145. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001;56(1):127-9. (Pubitemid 32059669)
146. Bogdanovic N, Davidsson P, Volkmann I, Winblad B, Blennow K. Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: an immunohistochemical and quantitative study. J Neural Transm. 2000;107(4):463-78. (Pubitemid 30189419)
147. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers. 2005;10(Suppl 1):S10-23. doi:10.1080/13547500500216546.
148. Il'yasova D, Morrow JD, Ivanova A, Wagenknecht LE. Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. Ann Epidemiol. 2004;14(10):793-7. doi:10.1016/j.annepidem.2004.03.003. (Pubitemid 39446401)
149. Janicka M, Kot-Wasik A, Kot J, Namiesnik J. Isoprostanes-biomarkers of lipid peroxidation: their utility in evaluating oxidative stress and analysis. Int J Mol Sci. 2010;11(11):4631-59. doi:10.3390/ijms11114631.
150. Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res. 2007;48(7):1607-17. doi:10.1194/jlr.M700097-JLR200. (Pubitemid 47312022)
151. Klawitter J, Haschke M, Shokati T, Klawitter J, Christians U. Quantification of 15-F2t-isoprostane in human plasma and urine: results from enzyme-linked immunoassay and liquid chromatography/tandem mass spectrometry cannot be compared. Rapid Commun Mass Spectrom. 2011;25(4):463-8. doi:10.1002/rcm.4871.
152. Tsikas D, Suchy MT. Assessment of urinary F(2)-isoprostanes in experimental and clinical studies: mass spectrometry versus ELISA. Hypertension. 2012;60(2):e14; author reply e5. doi:10.1161/HYPERTENSIONAHA.112.199315.
153. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med. 2001;125(4):510-2. doi:10.1043/0003-9985(2001)125〈0510: CFATAF〉2.0.CO;2. (Pubitemid 32291556)
154. Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, et al. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry. 2010;68(10):913-21. doi:10.1016/j.biopsych.2010.07.011.
155. Duits FH, Kester MI, Scheffer PG, Blankenstein MA, Scheltens P, Teunissen CE, et al. Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE epsilon4 carriers. J Alzheimers Dis. 2013;36(3):563-70. doi:10.3233/JAD-122227.
156. Kester MI, Scheffer PG, Koel-Simmelink MJ, Twaalfhoven H, Verwey NA, Veerhuis R, et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging. 2012;33(8):1591-8. doi:10.1016/j. neurobiolaging.2011.05.013.
157. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 2002;52(2):175-9. doi:10.1002/ana.10272. (Pubitemid 34810597)
158. Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011;343(1):227-35. doi:10.1007/s00441-010-1034-0.
159. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094-9. doi:10.1038/ng.439.
160. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088-93. doi:10.1038/ng.440.
161. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832-40. doi:10.1001/jama.2010.574.
162. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429-35. doi:10.1038/ng.803.
163. Eikelenboom P, Hack CE, Kamphorst W, Rozemuller JM. Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer's disease. Res Immunol. 1992;143(6):617-20.
164. Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J. Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology. 2012;217(2):244-50. doi:10.1016/j.imbio.2011.07.017.
165. Daborg J, Andreasson U, Pekna M, Lautner R, Hanse E, Minthon L, et al. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. J Neural Transm. 2012;119(7):789-97. doi:10.1007/s00702-012-0797-8.
166. DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL, et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann Neurol. 2003;53(1):81-90. doi:10.1002/ana.10414. (Pubitemid 36083832)
167. Manral P, Sharma P, Hariprasad G, Chandralekha, Tripathi M, Srinivasan A. Can apolipoproteins and complement factors be biomarkers of Alzheimer's disease? Curr Alzheimer Res. 2012;9(8):935-43.
168. Lo CY, Wang PN, Chou KH, Wang J, He Y, Lin CP. Diffusion tensor tractography reveals abnormal topological organization in structural cortical networks in Alzheimer's disease. J Neurosci. 2010;30(50):16876-85. doi:10.1523/JNEUROSCI.4136-10.2010.
169. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2013. doi:10.3233/JAD-130098.
170. Grimmer T, Alexopoulos P, Tsolakidou A, Guo LH, Henriksen G, Yousefi BH, et al. Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer's disease. ScientificWorld-Journal. 2012;2012:712048. doi:10.1100/2012/712048.
171. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging. 2008;29(6): 812-8. doi:10.1016/j.neurobiolaging.2006.12.010. (Pubitemid 351601894)
172. Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Mark. 2005;21(2):93-101. (Pubitemid 40875153)